RT Article
T1 Biomarkers in Psychiatric Disorders
JF Cambridge quarterly of healthcare ethics
VO 31
IS 4
SP 444
OP 452
A1 Glannon, Walter
LA English
PB Cambridge Univ. Press
YR 2022
UL https://ixtheo.de/Record/1827982527
AB Central and peripheral biomarkers can be used to diagnose, treat, and potentially prevent major psychiatric disorders. But there is uncertainty about the role of these biological signatures in neural pathophysiology, and their clinical significance has yet to be firmly established. Psychomotor, cognitive, affective, and volitional impairment in these disorders results from the interaction between neural, immune, endocrine, and enteric systems, which in turn are influenced by a person’s interaction with the environment. Biomarkers may be a critical component of this process. The identification and interpretation of biomarkers also raise ethical and social questions. This article analyzes and discusses these aspects of biomarkers and how advances in biomarker research could contribute to personalized psychiatry that could prevent or mitigate the effects of these disorders.
K1 Treatment
K1 Schizophrenia
K1 Psychiatry
K1 Prevention
K1 Prediction
K1 Major Depressive Disorder
K1 Diagnosis
K1 biomarkers
DO 10.1017/S0963180122000056